Efficacy, safety, and exploratory biomarker analysis of rechallenge with immune checkpoint inhibitors combined with anlotinib in previously treated advanced non-small cell lung cancer
Rechallenge with ICIs plus anlotinib demonstrated encouraging efficacy and safety in pretreated advanced NSCLC. Additionally, ORM2 and SERPINA1 were associated with response and survival outcomes in patients treated with the combined ICI + anlotinib regimen and may represent candidate biomarkers of clinical benefit, warranting prospective validation.
Authors
- X. Pu
- Xiong Yi
- H Yang
- Chunhua Zhou
- Li Liu
- Wenjuan Jiang
Institutions
- Central South University (CN)
- Hunan Cancer Hospital (CN)
Publication Details
- Journal
- BMC Pulmonary Medicine
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1186/s12890-025-04093-y
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00